Sensus Healthcare, Inc. SRTS
We take great care to ensure that the data presented and summarized in this overview for Sensus Healthcare, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SRTS
View all-
Vanguard Group Inc Valley Forge, PA779KShares$6.7 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny409KShares$3.52 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA304KShares$2.61 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX290KShares$2.49 Million0.0% of portfolio
-
Morgan Stanley New York, NY185KShares$1.59 Million0.0% of portfolio
-
Two Sigma Investments, LP New York, NY154KShares$1.32 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA146KShares$1.26 Million0.0% of portfolio
-
Perritt Capital Management Inc Chicago, IL126KShares$1.08 Million0.39% of portfolio
-
Sachetta, LLC Lynnfield, MA121KShares$1.04 Million0.28% of portfolio
-
Invenire Partners, LP Ridgefield, CT119KShares$1.02 Million100.0% of portfolio
Latest Institutional Activity in SRTS
Top Purchases
Top Sells
About SRTS
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.
Insider Transactions at SRTS
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jul 21
2024
|
Javier Rampolla CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,935
-8.91%
|
$23,610
$6.0 P/Share
|
Jul 21
2024
|
Michael Sardano PRESIDENT AND GENERAL COUNSEL |
SELL
Payment of exercise price or tax liability
|
Direct |
3,935
-5.0%
|
$23,610
$6.0 P/Share
|
May 20
2024
|
John Heinrich |
SELL
Open market or private sale
|
Direct |
15,227
-20.26%
|
$91,362
$6.24 P/Share
|
May 17
2024
|
John Heinrich |
SELL
Open market or private sale
|
Direct |
4,773
-5.97%
|
$23,865
$5.95 P/Share
|
Jan 11
2024
|
Michael Sardano PRESIDENT AND GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+20.25%
|
-
|
Dec 19
2023
|
Magdalena Martinez CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
741
-7.06%
|
$1,482
$2.66 P/Share
|
Sep 14
2023
|
Joseph C Sardano CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
10,000
+0.84%
|
$20,000
$2.88 P/Share
|
Aug 28
2023
|
Michael Sardano PRESIDENT AND GENERAL COUNSEL |
BUY
Open market or private purchase
|
Direct |
1,000
+1.67%
|
$2,000
$2.99 P/Share
|
Aug 08
2023
|
Joseph C Sardano CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
10,000
+0.85%
|
$30,000
$3.86 P/Share
|
Aug 08
2023
|
Michael Sardano PRESIDENT AND GENERAL COUNSEL |
BUY
Open market or private purchase
|
Direct |
1,000
+1.7%
|
$3,000
$3.78 P/Share
|
Jul 31
2023
|
Javier Rampolla CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
3,935
-8.18%
|
$11,805
$3.03 P/Share
|
May 11
2023
|
John Heinrich |
BUY
Open market or private purchase
|
Direct |
10,000
+11.12%
|
$20,000
$2.86 P/Share
|
May 10
2023
|
Joseph C Sardano CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
7,925
+0.68%
|
$23,775
$3.0 P/Share
|
May 09
2023
|
Joseph C Sardano CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
17,075
+1.47%
|
$34,150
$2.99 P/Share
|
May 09
2023
|
Samuel O'Rear |
BUY
Open market or private purchase
|
Direct |
17,564
+10.9%
|
$52,692
$3.0 P/Share
|
May 08
2023
|
Samuel O'Rear |
BUY
Open market or private purchase
|
Direct |
2,436
+1.9%
|
$4,872
$2.95 P/Share
|
May 08
2023
|
Michael Sardano PRESIDENT AND GENERAL COUNSEL |
BUY
Open market or private purchase
|
Direct |
1,000
+1.73%
|
$3,000
$3.0 P/Share
|
Feb 01
2023
|
Javier Rampolla CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
742
-1.52%
|
$5,936
$8.84 P/Share
|
Jan 26
2023
|
Michael Sardano PRESIDENT AND GENERAL COUNSEL |
SELL
Payment of exercise price or tax liability
|
Direct |
3,745
-6.29%
|
$29,960
$8.96 P/Share
|
Jan 26
2023
|
Michael Sardano PRESIDENT AND GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+14.38%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 20K shares |
---|
Payment of exercise price or tax liability | 8.61K shares |
---|---|
Open market or private sale | 20K shares |